Abstract
COVID-19 is an extremely severe acute respiratory infection caused by the SARS-CoV-2 coronavirus. This virus infects various organs both through direct infection and through the body's immune response. The presence of a patient in a state of immunosuppression contributes to the development of diseases that can be caused by opportunistic viruses, bacteria or fungi, which under normal conditions do not cause pathology in healthy people without damage to the immune system. The results of examination of the oral cavity in dental patients who have undergone COVID-19 demonstrate a variety of manifestations of dental diseases in the oral cavity. At the moment, there is no direct evidence of what exactly the underlying factor in the development and exacerbation of chronic diseases in the oral cavity after is suffering a coronavirus infection. This may be the virus itself, as well as drugs that patients took during treatment. Due to the widespread spread of COVID-19, the number of dental patients with various diseases of the oral cavity that developed against the background of a new coronavirus infection is steadily growing, among which there are various lesions of the dental pulp, including chronic gangrenous pulpitis. Actual is the problem of effective diagnosis and rational drug therapy in the treatment of this form of pulpitis. One of the reasons causing complications in the treatment of chronic gangrenous pulpitis is the lack of therapeutic complexes that can completely eliminate the inflammatory process. Treatment of pulpitis according to the standard method and only with antimicrobial drugs does not provide sufficient efficiency, therefore, in medical complex, along with etiotropic, it is necessary to use medicinal substances of pathogenetic influence. In the work, based on research, the diagnosis and treatment of chronic gangrenous pulpitis was carried out in 58 patients who had previously undergone COVID-19. Pulposcopic examination revealed elements of Candida yeast-like fungi. The data obtained substantiate the necessity and expediency of introducing an antifungal drug in the treatment of chronic gangrenous pulpitis, as one of the components at the stage of temporary root canal filling during endodontic treatment of a tooth.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
